Passionate about using statistics to support oncology research in fighting cancer.
I provide statistical input into the design, conduct and analysis of clinical trials. I am involved in a number of cancer and non-cancer trials at different stage, including early phase and phase II trials. Some of these projects include PACMEL, SIMPLE, ATOM, FuroHF and BOSS. I also work as part of Trial Steering Committees, Trial Management Committees, and Data and Safety Monitoring Committees.
Beyond my medical statistics skills, I have expertise in survey and sample design, estimation, index number and census methodology, gained through two years’ experience at the National Statistics Office in Eritrea. I also have lecturing experience, specialising in teaching introductory statistics, biometry and experimental design at the undergraduate level.
I have research interests in the field of survival analysis, specifically in the area of Cox proportional hazard model and methods beyond proportional hazard model. I first came across this scenario during the final analysis of the PACMEL trial and shared my experience at the annual conference in survival analysis for junior researchers 2017 in Leicester.
I obtained my BSc in Statistics and Demography from the University of Asmara, Eritrea in 2004. In 2009, I was awarded a Chinese government scholarship for international students, through which I completed a Master's degree in Quantitative Economics at the Wuhan University of Technology, China in 2011. In 2015 I completed an MSc in Medical Statistics at the London School of Hygiene and Tropical Medicine, funded by a UK-EU tuition fee scholarship and the Council for Assisting Refugee Academics (CARA). I joined the Centre for Statistics in Medicine in November 2015 as a medical statistician.
In my free time, I volunteer as a support worker with Refugee Resource, helping refugees and homeless people in Oxford.
A practical application of time to event analysis in the presence of non-proportional hazards
Mohammed SB. et al, (2017)
A randomised phase 2 study of Paclitaxel with or without Trametinib or Pazopanib in advanced wild type BRAF melanoma
Middleton MR. et al, (2017)